Drug Trial Radar · NCT07489573
Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa
Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Jun 1, 2026
Primary completion
Sep 25, 2029
Study completion Nov 5, 2029
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a post-approval commitment study to evaluate efficacy, and safety of two dosing regimens of secukinumab (AIN457), 300 mg every four weeks (Q4W) and every two weeks (Q2W), in Chinese adult patients with moderate to severe hidradenitis suppurativa (HS).
Conditions
- Hidradenitis Suppurativa (HS)
Interventions
SecukinumabDrug
secukinumab 300 mg s.c. administered Q2W or Q4W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants achieving HiSCR50 at Week 16Time frame: Week 16
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Beijing, China · Recruiting
Novartis Investigative Site
Beijing, China · Recruiting
Novartis Investigative Site
Shanghai, China · Recruiting
Novartis Investigative Site
Tianjin, China · Recruiting
Novartis Investigative Site
Guangzhou, Guangdong, China · Recruiting
Novartis Investigative Site
Shijiazhuang, Hebei, China · Recruiting
Novartis Investigative Site
Chengdu, Sichuan, China · Recruiting
Novartis Investigative Site
Hangzhou, Zhejiang, China · Recruiting
Novartis Investigative Site
Ningbo, Zhejiang, China · Recruiting
Novartis Investigative Site
Wenzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.